Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Assessing risk of venous thromboembolism in the patient with cancer.

Khorana AA, Connolly GC.

J Clin Oncol. 2009 Oct 10;27(29):4839-47. doi: 10.1200/JCO.2009.22.3271. Epub 2009 Aug 31. Review.

2.

Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.

Reitter EM, Kaider A, Ay C, Quehenberger P, Marosi C, Zielinski C, Pabinger I.

J Thromb Haemost. 2016 Feb;14(2):294-305. doi: 10.1111/jth.13218. Epub 2016 Jan 29.

PMID:
26662117
3.

New insights into cancer-associated thrombosis.

Sousou T, Khorana AA.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):316-20. doi: 10.1161/ATVBAHA.108.182196. Review.

4.

Identifying cancer patients at risk for venous thromboembolism.

Sousou T, Khorana A.

Hamostaseologie. 2009 Jan;29(1):121-4. Review.

PMID:
19151861
5.

Diagnosis and initial treatment of venous thromboembolism in patients with cancer.

Streiff MB.

J Clin Oncol. 2009 Oct 10;27(29):4889-94. doi: 10.1200/JCO.2009.23.5788. Epub 2009 Sep 8. Review.

PMID:
19738109
6.

Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.

Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V.

Clin Exp Med. 2013 May;13(2):85-97. doi: 10.1007/s10238-013-0230-0. Epub 2013 Mar 2. Review.

PMID:
23456539
7.

VTE risk assessment in cancer. Who needs prophylaxis and who does not?

Ay C, Pabinger I.

Hamostaseologie. 2015;35(4):319-24. doi: 10.5482/HAMO-14-11-0066. Epub 2015 Mar 5. Review.

PMID:
25740182
8.

Risk assessment and prophylaxis for VTE in cancer patients.

Khorana AA.

J Natl Compr Canc Netw. 2011 Jul 1;9(7):789-97.

PMID:
21715725
9.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
10.

D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.

Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I.

J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.

PMID:
19636003
11.

Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients.

Ay C, Pabinger I.

Thromb Res. 2012 Apr;129 Suppl 1:S6-9. doi: 10.1016/S0049-3848(12)70008-7.

PMID:
22682135
12.

Biomolecular markers of cancer-associated thromboembolism.

Hanna DL, White RH, Wun T.

Crit Rev Oncol Hematol. 2013 Oct;88(1):19-29. doi: 10.1016/j.critrevonc.2013.02.008. Epub 2013 Mar 21. Review.

13.

The role of thromboprophylaxis in cancer patients: emerging data.

Menapace LA, Khorana AA.

Curr Opin Hematol. 2010 Sep;17(5):450-6. doi: 10.1097/MOH.0b013e32833c0760. Review.

14.

Cancer-associated thrombosis: updates and controversies.

Khorana AA.

Hematology Am Soc Hematol Educ Program. 2012;2012:626-30. doi: 10.1182/asheducation-2012.1.626. Review.

PMID:
23233644
15.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.

J Clin Oncol. 2009 Oct 10;27(29):4919-26. doi: 10.1200/JCO.2009.22.3214. Epub 2009 Aug 31. Review.

16.

Venous thromboembolism: risk factors for recurrence.

Zhu T, Martinez I, Emmerich J.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):298-310. doi: 10.1161/ATVBAHA.108.182428. Review.

17.

Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score.

Connolly GC, Khorana AA.

Thromb Res. 2010 Apr;125 Suppl 2:S1-7. doi: 10.1016/S0049-3848(10)00227-6. Review.

PMID:
20433985
18.

[Estimation of venous thromboembolism risk with thrombotic biomarkers in cancer patients].

Jianlong M, Diansheng Z, Jing R.

Zhonghua Zhong Liu Za Zhi. 2015 Apr;37(4):283-9. Chinese.

PMID:
26462893
19.

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA; D-dimer Optimal Duration Study Investigators..

Ann Intern Med. 2015 Jan 6;162(1):27-34. doi: 10.7326/M14-1275.

PMID:
25560712
20.

Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism.

Van Haren RM, Valle EJ, Thorson CM, Jouria JM, Busko AM, Guarch GA, Namias N, Livingstone AS, Proctor KG.

J Trauma Acute Care Surg. 2014 Feb;76(2):443-9. doi: 10.1097/TA.0b013e3182a9d11d.

PMID:
24398771

Supplemental Content

Support Center